List of Antibodies Companies in Maryland - 43

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world's most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients' team – helping them advance today's ideas into tomorrow's medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and analytical testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world’s most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. With facilities located in the United States, ABL aims to be a seamless extension of our clients’ team – helping them advance today’s ideas into tomorrow’s medicines. ABL's CDMO service division specializes in the development and manufacturing of GMP cell banks and viral vectors from the bench to Phase I/II clinical trials. We aim to contributes to the success of our clients' ground-breaking innovations, including gene therapies, immunotherapies, viral vaccines, oncolytic viruses, and more. ABL's CDMO services include bulk drug substance production, fill/finish of drug products, process development, assay development and release testing.

AscentGene is a biotechnology company that provides high-quality cell lines and protein services to the life sciences community.

Avalo Therapeutics Inc. (Name changed from Cerecor Inc.) is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"​). Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets"​) from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.

BioFactura develops and commercializes biodefense drugs, novel drugs, and high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal choice for bringing these products to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.

Biologics Resources, LLC (BRLLC) is a Vaccines, immunotherapeutics and Biopharmaceuticals technology company.

BiOneCure Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative ADC drugs for the treatment of cancers. The company was founded in 2017 by a group of industry veterans who have worked in global biopharmaceutical companies. Their research focuses on creating innovative technology platforms and adopting a multifaceted approach to develop new medicines that exceed current standards. The current pipeline covers classic ADCs, bispecific ADCs, and bifunctional ADCs, aiming to be the first-in-class or the best-in-class products.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited; Juventas Cell Therapy Ltd.; Pharmathen Global BV; and Cleave Therapeutics, Inc. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.

Cellex has developed a rapid test for IgG and IgM antibodies to SARS-CoV-2. The company hastests that detect antibodies to multiple kinds of pathogens including HIV, HCV, Syphilis, HSV, and also makes tests for diabetes.Cellex received emergency use authorization (EUA) for its COVID-19 antibody test from the FDA for qSARS-CoV-2 IgG/IgM Rapid Test in 3/2020

CentryMed is a biopharmaceutical company located in Frederick, Maryland, neighboring the National Cancer Institute (NCI) and numerous pioneering biotechnology companies and supporting entities. Since its founding in 2018, CentryMed has been dedicated to discovering and developing safer and more effective biotherapeutics for the treatment of various diseases.

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

Fina Biosolutions, LLC was founded in 2006 by Dr. Andrew Lees with an initial focus on helping emerging market vaccine manufacturers learn to make affordable conjugate vaccines. The company offers bioconjugation, protein expression, purification, immunoassay design, analytics, training, and consulting services.

Fzata, Inc. is a oral biologics biopharmaceutical company based in Halethorpe, MD within the vibrant BioHealth Capital Region. Fzata’s vision is to reduce health inequities by expanding patient access to therapeutic biologics. This is made possible with our proprietary first-in-class oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. BioPYM enables orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, and more. Our oral biologic drug candidates are intended to help patients that inject biologic medicine by 1) offering affordable, non-refrigerated, convenient oral capsules, 2) improving quality of life with no needles and no need for health-care administration and 3) improving patient outcomes with expected high safety and high efficacy targeted to GI.

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.

Hememics uniquely uses graphene-based sensors with our patented bio preservatives to bring handheld, lab-quality testing performance to wherever needed – whether it is a farm, emergency room or battlefield. Our rugged, low-cost platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors. Our sensors can be individually programmed to detect molecular, antigen and antibody targets. We put a whole lab in your hand so you can make decisions when and wherever necessary – simplifying workflows with results within minutes.

Headquartered in North Bethesda, Maryland, Ibex Biosciences, Inc. ("Ibex") distinguishes itself in the early-stage biotech sector with its varied research and development approach. ​Ibex boasts a diverse portfolio that includes therapeutic antibodies, gene therapies, and regenerative medicine programs. We are proud of our proven capacity to discover and validate potential therapies from scratch, thus eliminating the need for external technology acquisitions or in-licensing. Our accomplishments are underscored by a series of in-vivo studies, which have delivered remarkable efficacy against a range of challenging medical conditions.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.

Infinity Bio is a technology company that provides detailed insights into the immune system using its proprietary antibody profiling platform. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity's assay, MIPSA, was developed at Johns Hopkins University in Ben Larman's Lab of Precision Immunology. It builds off decades of work in the fields of genomics, proteomics, immunology, and bioinformatics. Our assay was engineered to enable best-in-class turnaround times and cost. With a team of experienced professionals and a state-of-the-art facility, we are poised to make a significant impact to research and for our customers.

Kemp Proteins, LLC (formerly Kempbio) is a privately-owned, USA-based contract research and manufacturing organization located in Frederick, MD. Kemp Proteins is a premier provider of customized solutions for protein-related challenges. We are "Protein Problem-Solvers" focused on delivering best-in-class gene-to-protein services that optimize productivity and mitigate risk for innovators across the life sciences. The company has over two decades of experience in production of proteins and antibodies for use in basic research, diagnostics and drug development at the pre-clinical stage. Core expertise consists of gene-to-protein expression in mammalian, insect, and E. coli, hybridoma and stable cell-line development, analytical protein characterization, and Upstream/ Downstream process discovery/ optimization. Kemp Proteins' Process Discovery Services transition early therapeutic discovery programs to the biomanufacturing phase. Our teams identify key developability markers early in the discovery process while keeping scale and safety in mind. We use Process Analytical Tools in the initial discovery phase to identify the Critical Process Parameters required to derive Upstream and Downstream Processes that ensure Critical Quality Attributes are met. Once unit operations are defined for scale, we generate engineering and tox-material suitable for reference and NHP studies. The final processes are captured in Manufacturing Batch Records enabling seamless transitions to GMP facilities. Kemp Proteins has experience expressing and purifying a wide range of proteins from antibodies to multi-protein complexes and virus-like particles. The company operates under an ISO9001- and ISO13485-certified Quality Management System and the animal care and use program is AAALAC-accredited.

SeraCare, part of LGC's Clinical Diagnostics Division, enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.

Longhorn Vaccines and Diagnostics, LLC is a research company Headquartered out of 7272 Wisconsin Avenue Bethesda, MD 20814 United States. The R&D facility is at 19 Firstfield Rd Gaithersburg, MD 20878.

As a biopharmaceutical company, our team of dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our product candidates have been created primarily through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization platforms. These platforms are generally focused on the creation of antibodies, antibody derivatives, and antibody-like molecules for use as therapeutic agents. We currently have a pipeline of product candidates in human clinical testing, including seven immuno-oncology programs. Our product candidates and platforms have attracted partnerships with leading pharmaceutical and biotechnology companies around the globe.

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.

𝘐𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘏𝘦𝘢𝘭𝘵𝘩 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘴. MaximBio's comprehensive in-house capabilities provide you a world-class experience and confidence in our ability to keep costs down and deliver your products in time. At MaximBio, our team of dedicated professionals with over 25 years of expertise work to create a custom-fit, full service program in state-of-the-art facilities to meet all your needs and specifications: • FDA cGMP Registered for manufacture and distribution of medical devices • Compliant with 21 CFR Part 820 for medical devices • ISO 13485:2016 Certified for manufacturing and packaging of medical devices

Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.

We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on X @neoimmunetech

We’re focused on using our proven vaccine technology to protect health by developing our R&D assets and establishing partnerships. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our mission of ensuring broad access to our vaccines. It’s more than our job. It’s our passion. Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Based in Rockville, Maryland, OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.

OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full-length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens to develop protein assays for every human protein. In addition, OriGene offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be “Your Gene Company”, supplying everything a researcher needs for gene-based research. Visit us at https://www.origene.com

OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors.

Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent supports our partners in introducing 200 new products and manufacturing over 70 billion doses each year. Since becoming a publicly traded company in 2014, we have grown to become a community of approximately 19,000+ workers who support over 7,000 products for over 1,000 customers around the world. We share a common goal: to put patients first and help people around the world live better and healthier lives. Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. We have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging results. more products. better treatments. reliably supplied.™ Your talents, ideas, and passion are essential to our mission: to develop, manufacture, and supply products that help people live better, healthier lives. Join us! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s advanced technologies and collaboration with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help bring life-enhancing products to life. Grow with us. Be challenged. Make a personal impact. Visit https://careers.catalent.com/us/en to explore career opportunities

Protein BioSolutions provides viable solutions for scientists involved in DNA sequencing and in protein production, purification, characterization and crystallography.

SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics. Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$750M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas. GeneKey Biotech Ltd. Co. (www.genekeybio.com), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing of up to 2000L scale.

Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.

SeraCare, part of LGC's Clinical Diagnostics Division, enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.

Sigmovir Biosystems is a biotechnology company that specializes in the cotton rat model of human infectious diseases.

Speed BioSystems is a biomedical research reagents company that offers high-quality products with speedy delivery services.

Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

VLP Therapeutics, Inc. (VLPT) was established in 2013 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland.

Zyngenia is a biotechnology company that develops highly specific, single molecule biotherapeutics targeting multiple physiologic pathways to treat complex diseases like cancer and inflammation.